The following three primary human UM cell lines were used. Mel 290
29 and Mel 270,
30 which were kindly provided by Hans E. Grossniklaus, MD (Emory Eye Center, Atlanta, GA, USA) and 92.1, which came from one of our laboratories (Leiden University Medical Center, Leiden, The Netherlands).
31 These cell lines were obtained from primary UM and are well characterized.
29–31 All cell lines were maintained in Roswell Park Memorial Institute medium 1640 (RPMI) supplemented with 2 mg/mL sodium hydrogen carbonate (Substrate Department at the Panum Institute, Copenhagen, Denmark), with 10% fetal calf serum (FCS; Seralab, West Sussex, UK), 300 μg/mL L-glutamine and 200 μg/mL penicillin/streptomycin (Gibco, Paisley, UK). There were 100,000 cells of Mel 270 and Mel 290, and 80,000 cells of 92.1 plated into 6-well plates (Becton Dickinson, Le Pont De Claix, France). When Mel 290 was confluent and Mel 270 and 92.1 were subconfluent, medium was changed for all the experiments to X-VIVO 15 serum-free medium (Lonza BioWhittaker, Verviers, Belgium) containing 300 μg/mL L-glutamine, 100 μg/mL penicillin/streptomycin, and 2.5 μg/mL amphotericin B (Gibco, Paisley, UK), which did not have an effect on the further growth of the UM cells as they grew until confluency. X-VIVO 15 serum-free medium was used to allow the downstream use of the supernatants from the UM cell lines in the monocyte migration assay. Supernatants were harvested for analysis from the UM cell lines after they were cultured in X-VIVO 15 serum-free medium for 64 hours at 37°C and 5% CO
2.